Novo bets on swift FDA review for oral diabetes drug semaglutide
The world’s top diabetes drug maker Novo Nordisk is in a hurry. As part of its fourth-quarter results on Friday, the company $NVO said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
